Interview: Guo-Lian Yu, Ph.D – Executive Chairman, Crown Bioscience International, Taiwan

1 (3)Guo-Liang Yu, executive chairman of Crown Bioscience International, on the innovation-driven approach he has instilled since joining in 2013 and how this unique technology platform company now stands as the world leader in drug efficacy testing, enabling leading pharmaceutical companies to identify the right patients for the right treatment in their quest to develop game-changing oncology, inflammatory, and diabetes treatments. You have achieved a lot in both science and business; co-inventing more than 420 patents and co-authoring 40 peer-reviewed scientific articles referenced by the scientific community more than 6000 times as well as founding and chairing Epitomics, a company that was acquired by Abcam for more than USD 170 million in 2012. What objective did you set yourself when becoming the executive chairman of Crown Bioscience in 2013?
"Now, Crown proudly stands as the top company in the world for drug efficacy in oncology and diabetes, while we are also rapidly building a strong capacity in immunology."
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report